Pharmaceutical Science Advances最新文献

{"title":"Recent progresses in combination cancer therapy using cyanine dye-based nanoparticles","authors":"Qian An ,&nbsp;Si-Rui Xiang ,&nbsp;You-Quan Zou","doi":"10.1016/j.pscia.2024.100040","DOIUrl":"10.1016/j.pscia.2024.100040","url":null,"abstract":"<div><p>Surgical resection, radiotherapy, and chemotherapy are traditional methods for cancer treatment. With the development of materials science, photodynamic, photothermal, and sonodynamic therapies have been established over the past few years. Despite these advances, the development of novel and efficient cancer treatment protocols remains highly desirable. Recently, combination therapy has emerged as a powerful tool for achieving this goal. In this context, cyanine-nanoparticles have attracted considerable interest. Cyanine dyes have high molar absorptivity, narrow absorption/emission bands, and also excellent biocompatibility. This has meant that they have been widely used in biomedical imaging and therapy. Cyanine nanoparticles assembled from cyanine dyes and amphiphilic polymers or liposomes are endowed with high biocompatibility and long-term circulation for cancer combination therapy. A plethora of cyanine–nanoparticle-based combination therapy systems have been reported, and research in this discipline continues to expand. In this review, we aim to summarize recent advances in the combination therapy of cancers using cyanine nanoparticles over the last five years (i.e., from 2018 to 2023), with an emphasis on the structures of cyanine dyes, design concepts, and combination strategies. Personal insights and challenges in this field are also discussed. We expect that this review will inspire creative progress in combination therapies based on cyanine nanoparticles and facilitate the investigation of future clinical applications.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000060/pdfft?md5=dd24426ea65b5644321f1dc848ea95f1&pid=1-s2.0-S2773216924000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140406373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The most recent advances in liquisolid technology: Perspectives in the pharmaceutical industry","authors":"Yaseen Hussain ,&nbsp;Jinghao Cui ,&nbsp;Amos Dormocara ,&nbsp;Haroon Khan","doi":"10.1016/j.pscia.2024.100038","DOIUrl":"10.1016/j.pscia.2024.100038","url":null,"abstract":"<div><p>Hydrophobic drugs exhibit altered bioavailability and pose other challenges at an industrial level due to their poor solubility and dissolution rates. In addition, poor flowability, compressibility, complex dosing schedules, and light-sensitivity problems associated with hydrophobic drugs have led to poor patient compliance. To overcome these problems at an industrial level, the liquid-solid technique is a promising approach for tackling such challenges. This study outlines the prementioned challenges related to hydrophobic drug candidates and introduces the liquisolid technique as a potential alternative using non-volatile water-miscible solvents, carrier agents, coating substances, and their subsequent applications in the pharmaceutical industry. Furthermore, this study highlights the role of liquisolid technology in achieving sustained-release kinetics, emphasizing its benefits in minimizing pH changes in drug release and enhancing photostability. The study aimed to explore the liquisolid technique as an important tool for improving drug delivery, overcoming solubility issues, and optimizing therapeutic outcomes. In addition, this manuscript holds significant importance by highlighting the applications and recent advances in liquisolid technology, focusing on industrial-level applications. Moreover, it is impressive that such a technique offers improved formulation options to enhance the safety and efficacy of therapy. Overall, this study serves as a valuable resource for researchers to overcome formulation challenges and optimize drug delivery in the pharmaceutical industry.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000047/pdfft?md5=28e7fad4f3931f73de3aa176469437b7&pid=1-s2.0-S2773216924000047-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140273362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and research progress of oncolytic virus","authors":"Yingyu Chen ,&nbsp;Mengyuan Tao ,&nbsp;Xuwei Wu ,&nbsp;Zheng Tang ,&nbsp;Yinfu Zhu ,&nbsp;Kunxiang Gong ,&nbsp;Yinger Huang ,&nbsp;Wenbo Hao","doi":"10.1016/j.pscia.2024.100037","DOIUrl":"10.1016/j.pscia.2024.100037","url":null,"abstract":"<div><p>Oncolytic viruses (OVs) are natural or genetically recombinant viruses that selectively infect and kill tumor cells without affecting normal cell growth. As a novel type of immunotherapy, OVs have been shown to activate antitumor immune responses, regulate the tumor microenvironment, and enhance the efficacy of immune checkpoint inhibitors. In this review article, we discuss the latest research on the characteristics, antitumor mechanisms, and status of OV research. In terms of mechanism of action, after targeting tumor cells, OVs not only directly lyse tumor cells but also exert antitumor effects through indirect approaches. As an emerging cancer treatment, OVs face challenges that need to be overcome. Finally, we summarize the challenges and prospects for the future application of OVs.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000035/pdfft?md5=d88b2383a920ee72888d00114bd11969&pid=1-s2.0-S2773216924000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140275801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of lycorine hydrochloride against diabetic nephropathy in high-fat diet and streptozotocin-induced diabetic mice","authors":"Kai-Li Fang ,&nbsp;Xin-Yu Qi ,&nbsp;Qing-Tong Han ,&nbsp;Lu-Zhou Chen ,&nbsp;Xiao-Ning Wang ,&nbsp;Zhen-Peng Xu ,&nbsp;Lu-Qing Shang ,&nbsp;Tao Shen","doi":"10.1016/j.pscia.2024.100035","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100035","url":null,"abstract":"<div><p>Diabetic nephropathy (DN) poses a significant risk to individuals with diabetes. Inflammation plays a crucial role in DN pathogenesis. Lycorine hydrochloride (LH) is derived from <em>Lycoris radiata</em> (L'Hér.). This herb has been identified as a potent anti-inflammatory molecule. Further studies indicated that LH displayed therapeutic potential against metabolic disorders, renal dysfunction, and fibrosis in a high-fat diet and streptozotocin-induced (HFD/STZ)-induced DN mouse model. Mechanistically, LH mitigated renal inflammation in DN mice by targeting NF-κB pathways and the NLRP3 inflammasome verified by <em>in vivo</em> study. <em>In vitro</em>, LH inhibited NLRP3 inflammasome activation induced by nigericin (Ng), monosodium urate (MSU), and ATP, reduced caspase-1 activation, and IL-1β release. Additionally, LH suppressed the NF-κB IS-induced activation, prevented nuclear translocation of NF-κB, and subsequently reduced the expression of downstream proteins COX2 and iNOS. Collectively, these results indicated that LH primarily improved hyperglycemia-induced renal function by reducing inflammation by targeting NF-κB and NLRP3 inflammasome, implying it is a promising therapeutic agent for DN.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000011/pdfft?md5=e5fb7692c1c50492d880fd4f179372d7&pid=1-s2.0-S2773216924000011-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive manufacturing in nano drug delivery systems","authors":"Md. Habibur Rahman ,&nbsp;Nilufar Yasmin Liza ,&nbsp;Khan Rajib Hossain ,&nbsp;Dipika Ramdas Kalambhe ,&nbsp;Md. Abu Shyeed ,&nbsp;Dilwar Hossain Noor","doi":"10.1016/j.pscia.2024.100036","DOIUrl":"10.1016/j.pscia.2024.100036","url":null,"abstract":"<div><p>The adoption of innovative mixing and fabrication technologies in the pharmaceutical industry has inspired research on nano-drugs and expanded the scope of study in the field. Researchers' interest in the recently discovered drug delivery nanoparticles has increased significantly. This interest is especially seen in the specific preparation of nanoparticles as drug carriers through the use of three-dimensional (3D) printing, a modern additive manufacturing (AM) technology. The benefits of 3D printing, especially at the nanoscale, make it an innovative technology that could revolutionize the pharmaceutical and regenerative medicine industries. The laborious creation of intricate structures made possible by nanoscale 3D printing brings up the possibility of developing nanomedicine and producing functioning tissues and organs. The uses of AM in nano drug delivery systems (NDDS) are highlighted in this study, with a focus on how it can improve drug release kinetics, enhance therapeutic efficacy, and minimize side effects. A new era of personalized medicine has begun with the development of patient-specific formulations made possible by the customization capabilities of 3D printing. This review discusses the various uses of AM in NDDS while addressing issues including scalability, biocompatibility, and regulatory concerns. This review highlights the developing integration between AM and nanotechnology in medicine delivery and discusses ongoing research activities and possible solutions. As this innovative technology develops further, it has the potential to completely change the pharmaceutical development field by providing fresh approaches to the complex problems of contemporary healthcare and advancing the ideas behind drug delivery.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000023/pdfft?md5=cf73c01823eaed30da7a3590cf259c58&pid=1-s2.0-S2773216924000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antimicrobial peptides: A novel and promising arsenal against methicillin-resistant Staphylococcus aureus (MRSA) infections","authors":"Tope T. Odunitan ,&nbsp;Adegboye O. Oyaronbi ,&nbsp;Fakuade A. Adebayo ,&nbsp;Paul A. Adekoyeni ,&nbsp;Boluwatife T. Apanisile ,&nbsp;Tolu D. Oladunni ,&nbsp;Oluwatosin A. Saibu","doi":"10.1016/j.pscia.2023.100034","DOIUrl":"10.1016/j.pscia.2023.100034","url":null,"abstract":"<div><p>Despite years of research, technological advancements, and the widespread use of vaccines and antibiotics as tools to combat microbial threats to humans, methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infections remain a serious threat to global healthcare systems. The challenge of MRSA is a result of the bacteria's remarkably rapid evolution and adaptation, building up a collection of resistance genes that defeat the mechanism of traditional antibiotics. Conventional antibiotics, including the most notable beta-lactam antibiotics, such as penicillin and cephalosporin, are increasingly inadequate against the rapid adaptability and resistance of MRSA. Consequently, the scientific community's therapeutic arsenal for battling MRSA infections is becoming increasingly limited, necessitating innovative interventions<strong>.</strong> Antimicrobial peptides (AMPs), with their precise targeting mechanisms and innate modifiability, have emerged as promising therapeutic agents. By selectively interrupting bacterial processes and boosting innate immunological responses, AMPs offer a multifaceted strategy. Modern biotechnological and bioinformatics advancements have enabled the refinement of AMPs for improved efficacy. This comprehensive review delves into the intricate facets of MRSA pathogenicity, determinants of resistance, foundational tenets of peptide-based therapeutics, and recent scientific breakthroughs. A comprehensive analysis of the current research landscape, clinical implications, and persistent challenges underscores the potential of precisely tailored peptides as formidable weapons for counteracting the enduring threat of MRSA infections.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000326/pdfft?md5=8b1f8fd80d3b9643c6673743091d39bf&pid=1-s2.0-S2773216923000326-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of LibidUp-PE supplement on premature ejaculation: A randomized, placebo-controlled double-blind, crossover study","authors":"Jagadeesan M ,&nbsp;Adhisaya A ,&nbsp;T. Srinivasan ,&nbsp;Alphienes Stanley Xavier ,&nbsp;Pavithra Anandan ,&nbsp;Rajappan Chandra Satish Kumar ,&nbsp;Thangavel Mahalingam Vijayakumar","doi":"10.1016/j.pscia.2023.100033","DOIUrl":"https://doi.org/10.1016/j.pscia.2023.100033","url":null,"abstract":"<div><p>Premature ejaculation (PE) is the most common male sexual dysfunction. Selective serotonin reuptake inhibitors (SSRIs) are currently recommended for PE. However, the side effects of SSRIs, such as nausea, vomiting, and xerostomia, pose challenges to clinicians. Simultaneously, evidence indicates that psychological and behavioral treatments are often insufficient. LibidUp-PE is a nutraceutical designed to enhance sexual wellness and contains a combination of essential amino acids to boost stamina and vigor, addressing concerns like erectile dysfunction (ED). This study aimed to assess the safety and efficacy of LibidUp-PE in the treatment of PE. In this crossover, double-blind, placebo-controlled trial, 76 patients with PE were randomly divided into two groups. Group A received LibidUp-PE, whereas Group B received a placebo for 12 weeks. Following a 2-week wash-out period, the groups switched treatments for another 12 weeks. Intravaginal ejaculatory latency time (IELT) and post-ejaculatory refractory time (PERT) were measured as the primary outcomes to evaluate PE improvement. Plasma serotonin levels were measured as secondary parameters using enzyme-linked immunosorbent assay. The results showed that LibidUp-PE significantly improved the IELT score, increasing from 0.8 ± 0.2 min to 2.9 ± 1.1 min (<em>p</em> &lt; 0.01). PERT scores also significantly decreased from 15.8 ± 1.7 min to 5.6 ± 0.6 min after 12 weeks of LibidUp-PE treatment. Plasma serotonin levels significant increased from 93.6 ± 7.8 ng/mL to 168.4 ± 12.8 ng/mL (<em>p</em> &lt; 0.001) with LibidUp-PE treatment. In contrast, no significant improvements were observed in the placebo group. Notably, none of the participants withdrew their consent due to adverse reactions, which is indicative of the safety and tolerability of LibidUp-PE. In conclusion, 12-week treatment with LibidUp-PE demonstrated a beneficial effect in reducing PE symptoms, as reflected by improved IELT, reduced PERT, and increased plasma serotonin levels. Therefore, LibidUp-PE could be a promising solution for individuals with PE.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000314/pdfft?md5=3802bdfde5ac6739968ead8e62214a4c&pid=1-s2.0-S2773216923000314-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138738896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracellularly driven chemical modifications of antimicrobial secondary metabolites: Potent mechanisms of self-resistance","authors":"Xiaohua Li ,&nbsp;Jianhua Ju","doi":"10.1016/j.pscia.2023.100032","DOIUrl":"10.1016/j.pscia.2023.100032","url":null,"abstract":"<div><p>Natural products (NPs), especially antibiotics, exhibit diverse bioactivities and often play critically important roles in dictating and/or driving medical, health, agricultural, animal husbandry, and cosmetic industry initiatives. An important realization in the field of NP applications is that both targeted pathogens and the antibiotic-producing hosts themselves have usually evolved a host of resistance strategies by which to protect themselves. Although the former class of microbes (pathogens) has come to be associated with the global antibiotic resistance crisis, mechanisms by which producing organisms become resistant or tolerant to the ill effects of their bioactive metabolites have begun to attract a great deal of attention. Studies aimed at understanding antibiotic resistance have shown that producer-bourne mechanisms of self-resistance are possible prototypes by which to understand corresponding resistance elements in antibiotic-resistant bacteria. Historically speaking, the most efficient and potent chemistries employed by pathogens to evade harm from antimicrobial NPs have evoked enzymatically-driven transformations. We summarize herein the primary chemical modifications known to impart upon bioactive NP-producing microbes a means of self-defense against their own antimicrobial secondary metabolites; in understanding these chemistries we expect to gain new insights into how antibiotic resistance mechanisms in targeted pathogens might be circumvented or prevented. Such a translation of knowledge has a high likelihood of advancing humanity's ability to counter drug-resistant pathogens.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100032"},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000302/pdfft?md5=9b7368c90310b0814596be32a9a53382&pid=1-s2.0-S2773216923000302-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139292184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis","authors":"Dongyang Gao ,&nbsp;Wenli Gao ,&nbsp;Zhiguang Zhai ,&nbsp;Wenxiang Zhu","doi":"10.1016/j.pscia.2023.100030","DOIUrl":"10.1016/j.pscia.2023.100030","url":null,"abstract":"<div><p>Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by irreversible lung dysfunction caused by fibroblast proliferation and excessive collagen deposition, is the result of persistent chronic inflammation of the lung parenchyma. Although the pathogenesis is not fully understood, the role of immune mechanisms such as innate immune response, adaptive immunity and immune regulation, and cytokines in the pathophysiological mechanism of pulmonary fibrosis have been gradually recognized. There are currently limited drugs available to treat IPF, and long-term use of these drugs may have many adverse effects. With the elucidation of the underlying immunological pathogenesis, the development of more valuable drugs targeting the immune system becomes possible. This review introduces the immunological pathogenesis of pulmonary fibrosis and the emerging drugs targeting the immune system in recent years, aiming to provide insights into the mechanism and treatment direction of pulmonary fibrosis.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100030"},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000284/pdfft?md5=ede37c38ed8fc0e930b29c60115f85e3&pid=1-s2.0-S2773216923000284-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139296634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sclareol exerts an anti-inflammatory effect, possibly through COXs inhibition pathway: In vivo and in silico studies","authors":"Abdullah Al Shamsh Prottay ,&nbsp;Mehedi Hasan Bappi ,&nbsp;Md Showkoth Akbor ,&nbsp;Afia Ibnath Asha ,&nbsp;Md Shimul Bhuia ,&nbsp;Aqib Adnan Shafin ,&nbsp;Md Nayem Mia ,&nbsp;Mohammad S. Mubarak ,&nbsp;Micheline de Azevedo Lima ,&nbsp;Henrique Douglas Melo Coutinho ,&nbsp;Muhammad Torequl Islam","doi":"10.1016/j.pscia.2023.100029","DOIUrl":"https://doi.org/10.1016/j.pscia.2023.100029","url":null,"abstract":"<div><p>Chronic and severe inflammation results in many diseases and disorders in humans. Currently, available conventional anti-inflammatory drugs have numerous mild-to-severe side effects. Thus, there is a need for safe, effective, affordable, and alternative anti-inflammatory drugs. This study aimed to evaluate the anti-inflammatory effect of sclareol (SCL), a diterpene alcohol that is the principal ingredient in the refined oil of <em>Salvia sclarea</em> (L.), through <em>in vivo</em> and <em>in silico</em> studies. First, we examined the individual and combined effects of SCL (5, 10, and 20 mg/kg) and standard drugs celecoxib (CXB) or ketoprofen (KPN) at 42 mg/kg (p.o.) on the formalin-induced inflammatory <em>Swiss</em> mice. Additionally, an <em>in silico</em> analysis was conducted to evaluate the potential anti-inflammatory mechanism of this study. For this, we examined the potentiality of SCL and standards to interact with cyclooxygenase (COX) -1 and COX-2 receptors. Our findings suggest that SCL exhibits a dose-dependent anti-inflammatory effect in mice. SCL-20 mg/kg significantly reduced the number of paw licks and paw edema diameters. Moreover, SCL-20 combined with CXB-42 and KPN-42 demonstrated better anti-inflammatory effects. In comparison to the standards, SCL revealed a comparable binding interaction with COX-1 and COX-2 receptors in the molecular docking study. Furthermore, SCL displayed remarkable pharmacokinetic characteristics. In conclusion, SCL significantly and dose-dependently reduced the number of paw licks and edema diameters in animals. Thus, SCL may be responsible for producing an anti-inflammatory effect by interacting with COX-1 and COX-2 receptors.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100029"},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000272/pdfft?md5=c8ae6819910be7c13da5759b87e9ef94&pid=1-s2.0-S2773216923000272-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138484084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}